{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:42:33Z","timestamp":1778103753726,"version":"3.51.4"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,3]]},"DOI":"10.7759\/cureus.18462","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T13:32:04Z","timestamp":1633354324000},"source":"Crossref","is-referenced-by-count":3,"title":["The Great Imitator: Latent Neurosyphilis Revealed After Initiation of the Immunosuppressive Drug Secukinumab"],"prefix":"10.7759","author":[{"given":"Allison","family":"Duncan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Zingas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K086","article-title":"Reexamining syphilis: an update on epidemiology, clinical manifestations, and management","volume":"42","author":"Kent ME","year":"2008","unstructured":"Kent ME, Romanelli F. Reexamining syphilis: an update on epidemiology, clinical manifestations, and management. Ann Pharmacother. 2008, 42:226-36. 10.1345\/aph.1K086","journal-title":"Ann Pharmacother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.73","article-title":"Syphilis","volume":"3","author":"Peeling RW","year":"2017","unstructured":"Peeling RW, Mabey D, Kamb ML, Chen XS, Radolf JD, Benzaken AS. Syphilis. Nat Rev Dis Primers. 2017, 3:17073. 10.1038\/nrdp.2017.73","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14744\/nci.2015.96268","article-title":"Neurosyphilis: a case report","volume":"2","author":"Toptan T","year":"2015","unstructured":"Toptan T, Ozdilek B, Kenangil G, Ulker M, Domac FM. Neurosyphilis: a case report. North Clin Istanb. 2015, 2:66-8. 10.14744\/nci.2015.96268","journal-title":"North Clin Istanb"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3201\/eid2305.161556","article-title":"The discovery of penicillin\u2014new insights after more than 75 years of clinical use","volume":"23","author":"Gaynes R","year":"2017","unstructured":"Gaynes R. The discovery of penicillin\u2014new insights after more than 75 years of clinical use. Emerg Infect Dis. 2017, 23:849-53. 10.3201\/eid2305.161556","journal-title":"Emerg Infect Dis"},{"key":"ref5","unstructured":"Sexually transmitted disease surveillance 2018. (2019). Accessed. January 7, 2021: https:\/\/www.cdc.gov\/std\/stats18\/syphilis.htm."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30833-X","article-title":"Syphilis","volume":"391","author":"Barnett R","year":"2018","unstructured":"Barnett R. Syphilis. Lancet. 2018, 391:1471. 10.1016\/S0140-6736(18)30833-X","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2012-000314","article-title":"Old adversaries, modern mistakes: neurosyphilis","volume":"13","author":"Proudfoot M","year":"2013","unstructured":"Proudfoot M, McLean B. Old adversaries, modern mistakes: neurosyphilis. Pract Neurol. 2013, 13:174-7. 10.1136\/practneurol-2012-000314","journal-title":"Pract Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2019.26.4.278","article-title":"A case of rapid progressive neurosyphilis in patient with ankylosing spondylitis who is treating anti-interleukin 17A monoclonal antibody, secukinumab","volume":"26","author":"Lee SJ","year":"2019","unstructured":"Lee SJ, Park HK, Kim YS. A case of rapid progressive neurosyphilis in patient with ankylosing spondylitis who is treating anti-interleukin 17A monoclonal antibody, secukinumab. J Rheum Dis. 2019, 26:278-81. 10.4078\/jrd.2019.26.4.278","journal-title":"J Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13189","article-title":"Secondary syphilis infection under treatment with ustekinumab","volume":"42","author":"Uslu U","year":"2017","unstructured":"Uslu U, Heppt F, Sticherling M. Secondary syphilis infection under treatment with ustekinumab. Clin Exp Dermatol. 2017, 42:836-8. 10.1111\/ced.13189","journal-title":"Clin Exp Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/71897-the-great-imitator-latent-neurosyphilis-revealed-after-initiation-of-the-immunosuppressive-drug-secukinumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:29Z","timestamp":1707507029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/71897-the-great-imitator-latent-neurosyphilis-revealed-after-initiation-of-the-immunosuppressive-drug-secukinumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,3]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.18462","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,3]]}}}